📊 MRKR Key Takeaways
Is MRKR a Good Investment? Thesis Analysis
Marker Therapeutics is a pre-revenue stage biopharmaceutical company burning cash at an unsustainable rate with severe profitability challenges and declining revenue. The company's operating losses of -$12.9M against only $3.5M in revenue, combined with negative free cash flow of -$12.1M, indicate fundamental business execution issues that cannot be sustained.
Why Buy MRKR? Key Strengths
- Strong liquidity position with $16.1M in cash representing 84% of total assets
- Minimal debt burden with zero long-term debt and favorable 8.39x current ratio
- Stockholders' equity of $16.8M provides some balance sheet cushion
MRKR Investment Risks to Consider
- Revenue declining 46.2% YoY while operating losses remain extremely high, indicating accelerating business deterioration
- Negative free cash flow of -$12.1M annually will deplete the $16.1M cash balance within approximately 16 months at current burn rate
- Pharmaceutical development stage company with no clear path to profitability; no gross margin data suggests product commercialization challenges or lack of marketed products
- Operating margin of -363.5% and net margin of -343.0% represent unsustainable economics requiring significant revenue growth or cost restructuring
- No insider buying activity in last 90 days suggests lack of confidence from management in near-term prospects
Key Metrics to Watch
- Quarterly cash burn rate trend and months of runway remaining
- Revenue trajectory - stabilization or further decline in top-line
- Operating expense structure and ability to reduce burn while advancing pipeline
- Clinical trial progress and partnerships that could validate business model
- Cash position and need for capital raise at potentially unfavorable terms
MRKR Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 8.39x current ratio provides a solid financial cushion.
MRKR Profitability Ratios
MRKR vs Healthcare Sector
How Marker Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MRKR Overvalued or Undervalued?
Based on fundamental analysis, Marker Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MRKR Balance Sheet & Liquidity
MRKR 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Marker Therapeutics, Inc.'s revenue has grown significantly by 431% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.19 indicates the company is currently unprofitable.
MRKR Growth Metrics (YoY)
MRKR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.2M | -$2.0M | $-0.12 |
| Q2 2025 | $861.2K | -$2.2M | $-0.25 |
| Q1 2025 | $349.1K | -$2.4M | $-0.27 |
| Q3 2024 | $257.6K | -$2.3M | $-0.26 |
| Q2 2024 | $762.7K | -$2.2M | $-0.25 |
| Q1 2024 | $1.2M | -$2.4M | $-0.27 |
| Q3 2023 | $257.6K | -$3.0M | $-0.34 |
| Q2 2023 | $762.7K | -$2.5M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MRKR Capital Allocation
MRKR SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Marker Therapeutics, Inc. (CIK: 0001094038)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRKR
What is the AI rating for MRKR?
Marker Therapeutics, Inc. (MRKR) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRKR's key strengths?
Claude: Strong liquidity position with $16.1M in cash representing 84% of total assets. Minimal debt burden with zero long-term debt and favorable 8.39x current ratio.
What are the risks of investing in MRKR?
Claude: Revenue declining 46.2% YoY while operating losses remain extremely high, indicating accelerating business deterioration. Negative free cash flow of -$12.1M annually will deplete the $16.1M cash balance within approximately 16 months at current burn rate.
What is MRKR's revenue and growth?
Marker Therapeutics, Inc. reported revenue of $3.5M.
Does MRKR pay dividends?
Marker Therapeutics, Inc. does not currently pay dividends.
Where can I find MRKR SEC filings?
Official SEC filings for Marker Therapeutics, Inc. (CIK: 0001094038) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRKR's EPS?
Marker Therapeutics, Inc. has a diluted EPS of $-0.79.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MRKR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Marker Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MRKR stock overvalued or undervalued?
Valuation metrics for MRKR: ROE of -72.4% (sector avg: 15%), net margin of -343.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MRKR stock in 2026?
Our dual AI analysis gives Marker Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MRKR's free cash flow?
Marker Therapeutics, Inc.'s operating cash flow is $-12.0M, with capital expenditures of $99.8K. FCF margin is -341.6%.
How does MRKR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -343.0% (avg: 12%), ROE -72.4% (avg: 15%), current ratio 8.39 (avg: 2).